首页> 外文OA文献 >A controlled trial of value-based insurance design – The MHealthy: Focus on Diabetes (FOD) trial
【2h】

A controlled trial of value-based insurance design – The MHealthy: Focus on Diabetes (FOD) trial

机译:基于价值的保险设计的对照试验 - mHealthy:专注于糖尿病(FOD)试验

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Abstract Background Diabetes affects over 20 million Americans, resulting in substantial morbidity, mortality, and costs. While medications are the cornerstone of secondary prevention, many evidence-based therapies are underutilized, and patients often cite out-of-pocket costs as the reason. Value-based insurance design (VBID) is a 'clinically sensitive' refinement to benefit design which links patient cost-sharing to therapy value; the more clinically beneficial (and valuable) a therapy is for a patient, the lower that patient's cost-sharing should be. We describe the design and implementation of MHealthy: Focus on Diabetes (FOD), a prospective, controlled trial of targeted co-payment reductions for high value, underutilized therapies for individuals with diabetes. Methods The FOD trial includes 2,507 employees and dependents with diabetes insured by one large employer. Approximately 81% are enrolled in a single independent-practice association model health maintenance organization. The control group includes 8,637 patients with diabetes covered by other employers and enrolled in the same managed care organization. Both groups received written materials about the importance of adherence to secondary prevention therapies, while only the intervention group received targeted co-payment reductions for glycemic agents, antihypertensives, lipid-lowering agents, antidepressants, and diabetic eye exams. Primary outcomes include medication uptake and adherence. Secondary outcomes include health care utilization and expenditures. An interrupted time series, control group design will allow rigorous assessment of the intervention's impact, while controlling for unrelated temporal trends. Individual patient-level baseline data are presented. Discussion To our knowledge, this is the first prospective controlled trial of co-payment reductions targeted to high-value services for high-risk patients. It will provide important information on feasibility of implementation and effectiveness of VBID in a real-world setting. This program has the potential for broad dissemination to other employers and insurers wishing to improve the value of their health care spending.
机译:摘要背景糖尿病影响了超过2000万美国人,导致了高发病率,高死亡率和高成本。尽管药物是二级预防的基石,但许多循证疗法并未得到充分利用,并且患者经常将自付费用作为原因。基于价值的保险设计(VBID)是对“临床敏感”的改进,以使患者的费用分摊与治疗价值相关联。对患者而言,临床治疗越有益(且有价值),患者的费用分担就应该越低。我们描述了“ MHealthy:关注糖尿病”(FOD)的设计和实施,这是一项针对糖尿病患者的针对高价值,未充分利用的疗法的有针对性的共同付款减少的前瞻性对照试验。方法FOD试验包括2,507名雇员和一名大型雇主为患有糖尿病的家属提供保险。大约81%的学生参加了一个独立的实践协会模型健康维护组织。对照组包括8637名糖尿病患者,这些患者由其他雇主承保,并加入了同一家托管医疗机构。两组都收到了有关坚持二级预防疗法重要性的书面材料,而只有干预组收到了针对性的针对降糖药,降压药,降脂药,抗抑郁药和糖尿病眼科检查的共同付款减免。主要结局包括药物摄取和依从性。次要结果包括医疗保健利用和支出。中断的时间序列,对照组的设计将允许对干预措施的影响进行严格评估,同时控制无关的时间趋势。显示了各个患者水平的基线数据。讨论据我们所知,这是针对针对高风险患者的高价值服务减少共付额的首项前瞻性对照试验。它将提供有关在实际环境中实施VBID的可行性和有效性的重要信息。该计划有可能向希望提高其医疗保健支出价值的其他雇主和保险公司广泛传播。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号